Japan Tissue Engineering Co

Japan Tissue Engineering Co FCF Conversion

The FCF Conversion Rate (FCF/EBITDA) of Japan Tissue Engineering Co (7774.T) as of Nov 22, 2026 is 76.58 %. In the previous year, FCF Conversion Rate (FCF/EBITDA) was 87.93 % — a change of -12.91% (lower).

FCF Conversion

76.58 %

YoY

-12.91%

Last updated:

FCF Conversion Rate (FCF/EBITDA) of Japan Tissue Engineering Co is 2026 76.58 % . FCF Conversion Rate (FCF/EBITDA) of Japan Tissue Engineering Co was 2025 87.93 % . It decreases by -12.91% lower compared to the previous year.

The Japan Tissue Engineering Co FCF Conversion history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Conversion
Date
FCF Conversion
Jan 1, 2019
139.54 JPY
Jan 1, 2020
59.59 JPY
Jan 1, 2021
98.97 JPY
Jan 1, 2022
65.84 JPY
Jan 1, 2023
105.81 JPY
Jan 1, 2024
54.64 JPY
Jan 1, 2025
87.93 JPY
Jan 1, 2026
76.58 JPY
The Japan Tissue Engineering Co FCF Conversion history
YEARFCF ConversionYoY
76.58 %-12.91%
87.93 %+60.92%
54.64 %-48.36%
105.81 %+60.69%
65.84 %-33.47%
98.97 %+66.08%
59.59 %-57.30%
139.54 %-47.07%
263.62 %+1,451.17%
16.99 %-80.79%
88.45 %-50.78%
179.71 %+50.01%
119.80 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Japan Tissue Engineering Co Stock analysis

What does Japan Tissue Engineering Co do? Japan Tissue Engineering Co., Ltd. generates revenue through three business segments. The Regenerative Medicine Product segment sells autologous cultured epidermis JACE and autologous cultured cartilage JACK to medical institutions. The Regenerative Medicine Outsourcing segment offers CDMO, CRO, consulting, and contract manufacturing services for cell processed products. The Research and Development Support segment sells human cultured tissues developed using the company's advanced culture technology. Medical institutions purchase regenerative medicine products, while pharmaceutical and biotech companies utilize outsourcing services for cell-based therapies. The company's products are sold to healthcare providers and research-focused clients across Japan and potentially internationally. The Regenerative Medicine Product segment focuses on selling JACE and JACK, which are used in medical treatments requiring tissue regeneration. These products are specifically designed for autologous use, meaning they are derived from the patient's own cells. The Outsourcing segment provides specialized services to support the development and manufacturing of cell-based therapies, targeting pharmaceutical and biotech firms. The Research and Development Support segment supplies tissues for research applications, leveraging the company's internal technology to meet client needs in scientific development. JACE and JACK are key products in the Regenerative Medicine Product segment, directly sold to medical institutions for clinical use. The Outsourcing segment serves as a service provider for cell therapy development, offering CDMO and CRO capabilities. The Research and Development Support segment's human cultured tissues are marketed to research organizations seeking advanced cell culture solutions. All segments contribute to the company's revenue by addressing specific needs in regenerative medicine and cell therapy development. Japan Tissue Engineering Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Japan Tissue Engineering Co stock

FCF Conversion Rate (FCF/EBITDA) of Japan Tissue Engineering Co is 76.58 % in 2026.

FCF Conversion Rate (FCF/EBITDA) of Japan Tissue Engineering Co changed from 87.93 % to 76.58 %, representing a -12.91% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of FCF Conversion Rate (FCF/EBITDA) Japan Tissue Engineering Co since 2006 – with annual values, charts, and detailed analysis.

FCF conversion measures how effectively EBITDA converts to free cash flow. Higher conversion indicates efficient capital allocation and low maintenance costs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare FCF Conversion Rate (FCF/EBITDA)'s Japan Tissue Engineering Co with sector peers and the industry average to assess whether it is attractive.

To evaluate FCF Conversion Rate (FCF/EBITDA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for FCF Conversion Rate (FCF/EBITDA).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Japan Tissue Engineering Co

All Key Metrics — Japan Tissue Engineering Co